Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 70 or older, or people aged 60–69 who have a reduced ability to carry out daily activities due to their health condition (confirm with trial site regarding activity level scoring)
- People who have not previously received any treatment for their DLBCL, including chemotherapy, targeted therapy, immunotherapy, or radiation directed at the lymphoma (minor procedures such as a diagnostic biopsy do not disqualify someone)
- People who have been diagnosed with a specific type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that tests positive for CD20, C-MYC, and Bcl-2 markers, confirmed by a tissue sample analysis
- People who have at least one area of lymphoma that shows up clearly on a specific type of scan (PET-CT scan using a radioactive sugar tracer)
- People whose blood test results at the screening stage meet certain minimum levels for red blood cells, white blood cells, and platelets, and whose kidney and liver function fall within acceptable ranges (confirm exact values with trial site)
- People who are expected to live at least 6 months, as assessed by the treating doctor
- People who are able to understand the study and sign a consent form voluntarily
- Both males and females are eligible
Who may not be able to join:
- People who have, or have previously had, another active cancer
- People who have previously been treated with a drug called Chidamide or with the R-CHOP chemotherapy regimen, or who have a medical reason why they cannot receive any part of the CHOP chemotherapy combination (including prior treatment with a type of drug called anthracyclines)
- People who have had a severe allergic reaction to certain types of antibody-based medicines (monoclonal antibodies), or who are known to be sensitive or allergic to products derived from mice
- People currently diagnosed with certain other specific subtypes of lymphoma, including grey zone lymphoma, Burkitt lymphoma, lymphoma affecting the central nervous system, or several other named subtypes (confirm full list with trial site)
- People who have had a heart attack, unstable chest pain, or another significant heart condition within the past 12 months, or who have had a heart procedure such as a stent or angioplasty within the past 12 months
- People who have an active infection (bacterial, fungal, or viral) that is not under control, or who have active bleeding from an organ
- People who are pregnant or breastfeeding
- People who have taken part in another clinical trial within the past 6 months
- People who have any other condition that the trial doctor considers would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Huilai Zhang, Tianjin Medical University Cancer Insititute & Hospital
Phone: +86-18622221228
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete Response Rate (CRR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.